Vagus nerve stimulation in 15 children with therapy resistant epilepsy; its impact on cognition, quality of life, behaviour and mood  by Hallböök, Tove et al.
Seizure (2005) 14, 504—513www.elsevier.com/locate/yseizVagus nerve stimulation in 15 children with therapy
resistant epilepsy; its impact on cognition, quality
of life, behaviour and mood
Tove Hallbo¨o¨k a,*, Johan Lundgren a, Karin Stjernqvist b, Go¨sta Blennow a,
Lars-Go¨ran Stro¨mblad c, Ingmar Rose´n caDepartment of Paediatrics, University Hospital, SE-221 85 Lund, Sweden
bDepartment of Psychology, Lund University, Lund, Sweden
cDepartment of Clinical Neuroscience, University Hospital, Lund, Sweden
Received 10 November 2004
KEYWORDS
Epilepsy;
Vagus nerve
stimulation;
Cognitive
development;
Quality of life;
Mood;
Children
Summary
Purpose: Vagus nerve stimulation (VNS) is a neurophysiologic treatment for patients
with refractory epilepsy. There is growing evidence of additional quality of life (QOL)
benefits of VNS. We report the effects of VNS on seizure frequency and severity and
how these changes are related to cognitive abilities, QOL, behaviour and mood in 15
children with medically refractory and for surgery not eligible epilepsy.
Methods: Initially, and after 3 and 9 months of VNS-treatment, 15 children were
investigated with Bayley Scales of Infant Development (BSID), Wechsler Preschool and
Primary Scale of Intelligence (WPPSI-R), Wechlser Intelligence Scales for Children
(WISC-III) depending on the child’s level of functioning, a Visual Analogue Scale for
validating QOL, Child Behaviour Checklist (CBCL) for quantifying behaviour problems,
Dodrill Mood Analogue Scale and Birleson Depression Self-Rating Scale, and the
National Hospital Seizure Severity Scale (NHS3). A diary of seizure frequency was
collected.
Results: Six of 15 children showed a 50% or more reduction in seizure frequency; one
of these became seizure-free. Two children had a 25—50% seizure reduction. Two
children showed increased seizure frequency. In 13 of 15 children there was an
improvement in NHS3. The parents reported shorter duration of seizure and recovery
phase. There were no changes in cognitive functioning. Twelve children showed an
improvement in QOL. Eleven of these also improved in seizure severity and mood and
five also in depressive parameters.
Conclusion: This study has shown a good anti-seizure effect of VNS, an improvement
in seizure severity and in QOL and a tendency to improvement over time regardingDOI of original article: 10.1016/j.seizure.2005.07.004.
* Corresponding author. Tel.: +46 46173377.
E-mail address: tove.hallbook@skane.se (T. Hallbo¨o¨k).
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When anti-epileptic drugs fail, and epilepsy surgery
is found unfeasible or ineffective, there remains a
group of at least 10% of adults and 25% of children
with epilepsy in whom seizure control cannot be
achieved.
Repetitive vagus nerve stimulation (VNS) is a
neurophysiologic method for treatment of refrac-
tory epilepsy. VNS has proved to be efficacious and
well tolerated in adults.1,2
Paediatric studies have shown an even better and
more rapid response. More than 50% seizure reduc-
tion was reported in 27—57% of the children. Inter-
estingly these uncontrolled open studies also
showed a dramatic improvement in wellbeing and
quality of life (QOL). Parents or caregivers reported
an increase in alertness, memory-, motor-, verbal-
and cognitive-function that in part was unrelated to
the anti-seizure effect.3—6
More directed adult studies have revealed
improvement in mood, depression and memory
function.7—12 No VNS studies have revealed negative
effects on cognition in adults or in children.7—9 The
effects were independent of seizure control.
A few paediatric studies have indicated only
moderate improvement in these qualities.13,14
In this article we report the effects of VNS on
cognition, behaviour, mood and QOL in 15 children
with refractory epilepsy and how these changes are
related to seizure frequency and severity.
We also elucidate the difficulties in assessing and
in interpreting the results in a poorly investigated
but needful group of children with therapy-resistant
epilepsy and developmental impairment.
Effects on sleep quality and epileptiform EEG
abnormalities will be reported separately.
Methods
Subjects
The study group comprises 15 children (10 boys and
5 girls) aged 4—17 years (median 11 years) with the
diagnosis of epilepsy and absence of non-epileptic
seizures (Table 1). Epilepsy surgery has been per-
formed in four patients and found not applicable in
the others. Age of epilepsy onset was between 4months and 9 years (median three years). Duration
of epilepsy was 4—12 years (median 8.5 years). The
aetiology was unknown in three subjects. These
three had normal MRI-scans. All patients had been
on stable anti-epileptic drug medication for at least
3 months prior to the VNS implantation and during
the 9 months follow-up. Written informed consent
was obtained. The study was accepted by the Ethics
Committee of the Faculty of Medicine of the Lund
University.
VNS and VNS stimulation parameters
Vagus nerve stimulation is delivered via the Neuro
Cybernetic Prosthesis (NCP) System, Cyberonics,
Inc. The NCP is an implantable, multi-programmable
pulse generator that delivers current electrical sti-
mulation to the vagus nerve for the purpose of
suppressing and reducing the frequency and/or
severity of epileptic seizures. The VNS can be pro-
grammed externally with stimulation parameters
appropriate to individual patients. It can also be
activated by a hand-held-magnet.
The Vagus Nerve Stimulator is implanted subcu-
taneously below the clavicle on the left side. At the
end of the surgical procedure the device is pro-
grammed with the following parameters: output
current 0.25 mA; signal frequency 30 Hz; pulse-
width 500 ms; stimulation on-time 30 s; stimulation
off-time 5 min. During 4 weeks the output current is
increased in steps of 0.25 mA to 1—1.5 mA and is
then kept stable during the 9 months follow up.
Patient number 12 was changed to rapid stimulation
(stimulation on-time 7 s; stimulation off-time 12 s)
after 6 months.
Clinical outcome measures/seizures
During 3 months before initiation a diary of seizure
frequency and severity was collected together with
clinical data. These data serve as a baseline. Follow-
up assessments were performed at 3 and 9 months
after VNS-initiation. Each patient serves as his own
control.
The parents or caregiver filled in a protocol over
seizure frequency and was questioned about the
nature and timing of any seizures occurring during
the previous 3 months. Information about adverse
effects, compliance with medication over the samebehaviour, mood and depressive parameters. The improvement in seizure severity,
QOL, behaviour, mood and depressive parameters was not related to the anti-seizure
effect.
# 2005 BEA Trading Ltd. Published by Elsevier Ltd. All rights reserved.
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anti-epileptic drugs were measured.
The types of seizures, epilepsies and epileptic
syndromes were defined according to the classifica-
tion of the International League Against Epilepsy
including seizure semiology and electroencephalo-
gram characteristics before study entry.15,16
The following seizure typeswere recorded. Simple
partial seizures, complex partial seizures, partial
seizures evolving to secondary generalized tonic-
clonic seizures, generalized tonic-clonic seizures,
atonic seizures (drop attacks with complete relaxa-
tion of the body), atypical absences (moments of
decreased consciousness with minor accompanying
symptoms) and myoclonic seizures (short contrac-
tions of the face or limb). The myoclonic seizures
were not scored. The Seizure Severity was scored
with the National Hospital Seizure Severity Scale, a
further development of theChalfont Seizure Severity
Scale described by O’Donoghue et al.17
Cognitive functioning, QOL and behaviour
For assessment of cognitive abilities three different
tests were used depending on the child’s level of
functioning: BSID, Bayley Scales of Infant Develop-
ment, American version,18 WPPSI-R, Wechsler Pre-
school and Primary Scale of Intelligence, Swedish
version19 and WISC-III, Wechlser Intelligence Scales
for Children, Swedish version.20 For children assessed
with BSID the Mental Developmental Index (MDI) was
used to express the cognitive functioning and for
childrenassessedwithWPPSI-R andWISC-III Full Scale
IQ (IQ) was used. Fourteen children were assessed
before onset of VNS and 3 and 9 months after. In one
child the parents only wanted to perform the assess-
ment of cognitive functioningbefore onsetofVNSand
after 3 months and not after 9 months.
QOL, behaviour, mood and depression were
assessed by questionnaires and visual analogue
scales filled in by the parents, usually the mother.
Questionnaires were filled in immediately before
VNS-initiation and 3 and 9 months after.
To describe QOL a visual analogue scale (VAS) was
used with scores between 10 and +10. Zero in the
middle is the parent’s conception of the child’s QOL
immediately before VNS-initiation, 10 is 100%
reduction and +10 is 100% improvement of quality
of life.
Parent’s perceptions of the children’s general
behavioural problems were quantified by using
the total score of the Child Behaviour Checklist
(CBCL).21 The questionnaire comprises 115 items
and the parent was asked to rate, on a three point
scale, whether a behaviour problem was present or
not in the child and to what degree. The cut-offscore for manifest behaviour problems is 30 accord-
ing to Swedish norms for the scale.22
Mood was assessed by using a visual analogue
scale, which consists of 100 mm scales for 18 dimen-
sions (e.g. alert-drowsy; tense-relaxed), commonly
reported in the literature to be sensitive to drug
effects.23 The scale was translated and retranslated
into Swedish.
For measuring depression Birleson Depression
Self-Rating Scale (DSRS) was used. The scale has
been translated into Swedish and the wording of
the translation has made it acceptable both to
children24 and adolescents.25 It is an 18-item self-
report questionnaire in which the child is asked
to estimate his/her own situation during the last
week on a three-point scale. Scores of two, one or
zero, respectively, in the direction of disturbance,
refer to ‘‘most of the time’’, ‘‘sometimes’’ or
‘‘never’’.
Statistical evaluation
Wilcoxon signed rank test was used for comparisons
of the patient’s response before VNS initiation and 3
and 9 months after. Kruskal—Wallis test was used for
comparison between the three subgroups based on
treatment effect, before VNS initiation and 3 and 9
months after. Spearman rank correlation test was
used to calculate the correlation in degree of
improvement between QOL and NHS3 and QOL
and seizure reduction. The level of significance
was set at p < 0.05.Results
This prospective longitudinal study, presents the
response of VNS after 3 and 9 months in 15 children
with refractory epilepsy and in particular the effects
on seizure frequency and seizure severity in relation
to the effect on cognition, QOL, behaviour andmood.
Seizure frequency and severity
The seizure frequency decreased 50% or more in six
children; one of these became seizure-free. The
number of seizures decreased between 25 and
50% in two and decreased less than 25% in four. It
increased in two patients and was unchanged in one.
Without considering seizure type, 3 and 9 months
of VNS reduced the median seizure number from
pre-implantation 51 (range 2—200) to post-implan-
tation 18 (range 2—141) and 19 (range 0—112),
respectively. Thus the median seizure reduction
was 65% ( p = 0.02) at 3 and 63% (p = 0.04) at 9
months.
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Table 1 Demographics and clinical characteristics of the study group.
Patient no. Age at
study
onset
(year)
Sex Age at
epilepsy
onset
(year)
Epilepsy
type/
syndrome
Seizure
type
Etiology Previous
epilepsy
surgery
MRI Changes in seizure
frequency at 9
months (%)
1 10 M 0.25 Lennox-Gastaut GTCS Unknown No No Increase (33%)
2 9 M 2.5 Partial, Symt. CPS CD Yes L.TL res., MD Seizure free (100%)
3 15 F 3 Partial, Symt. CPS Encephalitis No No Reduction (<25%)
4 4 M 1 Partial, Symt. CPS CD Yes R.TL res., MD Reduction (<25%)
5 13 M 5 Lennox-Gastaut 28GTCS, AAbS HIE No R. occ. lesion, focal atrophy No change (0%)
6 11 M 4.5 CSWS SPS, 28GTCS HIE No L. lesion, atrophy Reduction (>50%)
7 15 M 5 Partial, Symt. SPS HIE No L. parietal lesion Reduction (50%)
8 9 F 0.5 Lennox-Gastaut 28GTCS HIE No R. Schiz., L.CD, CCA Reduction (50%)
9 17 M 9 Partial, Symt. CPS CD No Multiple prenatal lesions Increase (16%)
10 6 M 0.75 Partial, Symt. CPS, MS Unknown No No Reduction (<50%)
11 10 F 2 Partial, Symt. 28GTCS CD Yes L. parieto-occ. res., MD Reduction (<25%)
12 11 M 0.25 Lennox-Gastaut GTCS, AS, MS CD Yes R. frontal and occ. res., MD Reduction (25%)
13 16 M 7 Partial, Symt. CPS HIE No L. PVL, BG lesion Reduction (>50%)
14 12 F 3 Partial, Symt. CPS Unknown No No Reduction (>50%)
15 12 F 5 CSWS CPS Unknown No R. anterior hipp. atrophy Reduction (<25%)
Epilepsy and seizure types according to the International Classification of the International League Against Epilepsy. Abbreviations–—AS: atonic seizure; AAbS: atypical absence seizure; BG:
basal ganglia; CCA: corpus callosum agenesis; CD: cortical dysplasia; CPS: complex partial seizure; CSWS: continuous spike-wave during slow sleep; F: female; GTCS: generalized tonic-clonic
seizure; 28GTCS: secondary generalized tonic-clonic seizure; HIE: hypoxic-ischemic encephalopathy; hipp.: hippocampus; L.: left; M: male; MD: multiple dysplasia; MS: myoclonic seizure;
occ.: occipital; PVL: periventricular leukomalacia; R.: right; Res.: resection; Schiz.: schizencephaly; Symt.: symtomatic; TL: temporal lobe.
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Table 2 Reduction of seizure frequency according to seizure type initially and after 3 and 9 months of VNS-
treatment.
Patient no. Number of
patients
Before initiation
total number
of seizure
3 months after
initiation total
number of seizure
(% reduction)
9 months after
initiation total
number of seizure
(% reduction)
Complex partial seizures 8 325 207 (36%) 202 (37%)
2 53 5 0
3 19 18 18
4 78 63 75
9 6 7 7
10a 14 9 9
13 9 2 2
14 72 40 31
15 74 63 60
Generalized 2 131 130 (0%) 163 (24% increase)
1 75 91 100
12a 56 39 63
Secondary generalized 4 258 198 (23%) 163 (37%)
5a 5 6 10
6a 2 1 2
8 200 141 100
11 51 49 48
Simple partial seizures 2 13 11 (15%) 6 (54%)
6 11 9 5
7 2 2 1
Atonic drop attacks 1 76 37 (51%) 36 (53%)
12 76 37 36
Atypical absences 1 9 9 (0%) 4 (56%)
5 9 9 4
Myoclonic seizures 2 Yes No No
10 Yes No No
12 Yes No No
Seizure types according to the International Classification of the International League Against Epilepsy. The number of seizure was
collected from seizure diary and counted as the mean value of the last 3 months.
a Four patients had more than one seizure type.The results on different seizure types are pre-
sented in Table 2. Simple partial, complex partial
and atonic seizures seemed to decrease more than
other seizure types scored. Two children had myo-
clonic seizures that were not scored. In both cases
the myoclonic seizures ceased after 3 months.
Seizure severity, measured as NHS3, showed an
improvement both at 3 and 9 months (p < 0.001).
The median score at baseline, 3 and 9 months of
treatment were 12 (range 4—19), 9 (range 1—19)
and 9 (range 1—16), respectively. The parents
reported shorter seizure duration and shorter recov-
ery phase after a seizure.
Cognition
Six children were tested with BSID, one with
WPPSI-R, seven with WISC-III Full Scale and onewith WISC-III Verbal Scale. This child has a cerebral
palsy and was not able to fulfil the performance
test. All, but one child, were mentally retarded
(IQ < 70) at the assessment before onset of treat-
ment. In one child (12) the parents only wanted to
perform the assessment of cognitive functioning
before onset of VNS and after 3 months and not
after 9 months.
The results of the baseline to treatment and the
follow-up 3 and 9months after VNS implantation are
shown in Table 3. For most children there are no
differences in cognitive functioning before and
after VNS. Two children (6 and 7) improved their
IQ and one (11) child deteriorated. Four children
were severely mentally retarded with IQ < 30. For
them also mental age was calculated at the three
assessments but they showed no improvement over
time.
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Figure 1 (A) Percentage change of quality of life scores in 15 children initially, and after 3 and 9 months of vagus nerve
stimulation. (B) Percentage change of Child Behaviour Checklist (CBCL) scores in 15 children initially, and after 3 and 9
months of vagus nerve stimulation. (C) Percentage change of depression scores in 10 of the 15 children initially, and after
3 and 9 months of vagus nerve stimulation. (D) Percentage change of Dodrill Mood Analogue Scale scores in 14 children
initially, and after 3 and 9 months of vagus nerve stimulation.
Table 3 Results of assessments of cognitive abilities initially (baseline), and after 3 and 9 months of VNS-treatment.
Patient no. Age (year:month) Method Baseline MDIa/IQ 3 months MDIa/IQ 9 months MDIa/IQ
1 10:3 BSID <30 <30 <30
2 9:10 WISC 39 37 42
3 15:3 WISC 45 42 41
4 5:3 BSID 48 48 49
5 13:5 WPPSI 40 40 40
6 11:1 WISC 56 69 68
7 15:6 WISC 61 65 76
8 8:9 BSID <30 <30 <30
9 17:11 WISC 37 37 37
10 5:9 BSID 49 47 47
11 10:6 WISC 74 60 54
12 11:1 BSID <30 <30
13 16:6 WISC 42 42 42
14 11:2 BSID <30 <30 <30
15 12:0 WISC 37 37 37
BSID: Bayley Scales of Infant Development; WPPSI: Wechsler Preschool and Primary Scale of Intelligence; WISC: Wechlser Intelligence
Scales for Children; MDI: Mental Developmental Index.
a MDI was used for children assessed with BSID.
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The results of QOL and the behaviour scales are
presented in Fig. 1. Analysis of the estimation of
the parent’s conception of the child’s QOL reveals
significant improvement both after 3 and 9 months
of VNS treatment.
In CBCL higher scores indicate more problems. In
Dodrill Mood Analogue Scale higher scores indicate
improvement in mood and in DSRS higher scores
indicate more depressive symptoms. There seems
to be a tendency to an improvement in behaviour,
mood and depression parameters when using these
questionnaires although the changes are not signifi-
cant. The behaviour score was over the cut off score
for manifest behaviour problems in 11/15 children.
Seven of these improved. The four children with
behaviour score under the cut off score did not
change their score. One child with CSWS and epi-
sodes of ‘‘zombie-like’’ behaviour lasting for days
besides overt CPS had only a slight reduction in the
frequency of the CPS (16% and 17% at 3 and 9
months, respectively) but recovered considerably
in QOL and behaviour score, and from the ‘‘zombie-
like’’ episodes. CSWS is a therapy resistant, neuro-
physiologic and clinical entity with epileptiform
activity in >85% of non-REM sleep.26
When comparing the results of QOL and behaviour
between three subgroups based on seizure reduc-
tion, no difference was discerned ( p = 0.6 in QOL,
p = 0.6 in CBCL, p = 0.5 in Dodrill and p = 0.2 in DSRS
when comparing 9 months against baseline in the
three subgroups) (Table 4). However, there seemed
to be a correlation between improvement in QOL,
mood and seizure severity. In 13 of the 15 children
there was an improvement in NHS3. Twelve children
showed an improvement in QOL. Eleven also
improved in seizure severity and mood and 5 also
in depressive parameters. The number of children
with improvement in both QOL and NHS3 was higher
than QOL combined with seizure reduction. No cor-
relations in degree of improvement were found
(Fig. 2). (Spearman correlation coefficient was
0.32 and 0.40, respectively.) In general there was
a tendency of improvement over time in median
scores regarding behaviour, mood and depressive
parameters.
Side effects
No severe side effects were seen either from the
surgical procedure or from VNS itself.
Transient coughing and hoarseness for 1 or 2 days
after increasing the current was reported in four
patients. Weight loss was seen in one adolescent.
One had a non-transient pain and paresthesia in the
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Figure 2 Correlation between the percentage changes
in QOL and seizure frequency at 3 and 9 months after
initiation of vagus nerve stimulation. No correlation in
degree of improvement was found ( p = 0.25 and 0.40;
Spearman correlation coefficient).neck that was so disabling that QOL, behaviour score
and mood were affected and the stimulator was
withdrawn after the study was finished. One child
was complaining from breath shortness that did not
improve completely until we reduced the pulse
width from 500 to 250 ms after 9 months.
Discussion
This study confirms previous studies of vagus nerve
stimulation indicating better anti-seizure effect in
children compared to adults with >50% seizure
reduction in 40% of children. In addition our results
show improvement in QOL and indicate better beha-
viour-, mood- and depressive parameters after VNS.
Parker et al.5 and Majoie et al.14 reported less
good effect in children with severe encephalopathy.
Aldenkamp et al.13 suggested that the treatment
effect of VNS is related to the severity of the mental
impairment, with the most positive effects in
patients with less severe disabilities. In this study
there are fewer patients suffering from severe epi-
leptic encephalopathy and better anti-epileptic
effect in those with less mental retardation. This
supports the suggestions of better anti-seizure
effect in children with less severe impairment.
In this study 80% of the children had an improve-
ment in parent’s conception of the child’s QOL, butthe effect seemed not related to the anti-seizure
effects. One of the three patients with a worsening
in QOL had unchanged seizure frequency and two
patients with improved QOL had increased seizure
frequency. However, there seemed to be a correla-
tion between improvement in QOL, mood and sei-
zure severity. Eleven of the 12 children with
improvement in QOL also improved in seizure sever-
ity and mood and 5 also in depressive parameters.
The number of children with improvement in both
QOL and NHS3 was higher than QOL combined with
seizure reduction. No correlations in degree of
improvement were found (Fig. 2). Our results are
in accordance with previous reports with epilepsy
surgery. Reduction in seizure severity is significantly
correlated with improvement in QOL after corpus
callosotomy.27 Low seizure severity correlated with
higher health-related quality of life (HRQOL) ratings
for scales measuring social function, vitality, and
mental health after epilepsy surgery in a Swedish
multicenter study in patients from 16 years of age
and a >75% reduction of seizure frequency.28
We used parent’s conception of the child’s QOL
even though major concerns have been raised
regarding the accuracy and acceptability of parent
rating of children’s QOL. Ronen et al.29 showed that
there is a tendency for parents to score lower than
the child in QOL and performance status. In very
young children and in severely handicapped children
measurements can be based only on parent reports.
Parent reports may prove to be more reliable and
valid in long-term investigations because of the
rapid changes in children’s attitudes, abilities and
priorities as part of the developmental processes.
Our results suggest an improvement in mood and
some antidepressant effect. Studies in adults show a
marked antidepressant effect in patients suffering
from major depression.11 In our study no child had
depressive scores below the cut off for manifest
depression. True changes in depression parameters
might be difficult to determine in patients not
suffering from major depression.13 Scoring tests
better elucidating mood changes in children not
suffering a depressive disorder might have given
more truthfully results.
Our results in behavioural changes as a result of
VNS stimulation at 3 and 9 months did not show any
significant improvement. However, there seemed to
be an improvement over time. One could speculate
that the improvement in behaviour had not yet
occurred to its full extent after 9 months. A longer
follow up might show additional improvement.
Although caution must be taken when expressing
absence of differences in a small group, we cannot
find an association between anti-seizure effect and
improvement in QOL and behaviour, not even when
512 T. Hallbo¨o¨k et al.comparing between the subgroups based on seizure
reduction (Table 4).
We did not see any differences in cognitive
functioning before and after VNS. The two children
that improved their IQ had the highest baseline IQ.
This could support previous findings of VNS on
epileptiform activity that the treatment effect is
related to the severity of the mental impairment,
with the most positive effects in patients with less
severe disabilities. Aldenkamp et al.13 described
that cognitive and behavioural assessments are
difficult to use in this type of patients with epilepsy
and developmental impairment. Both testing and
interpretation of test results are challenging.
There is also a possibility that VNS does not affect
cognitive functioning in this type of patients. Ott
et al.30 discussed limitations in the CBCL behaviour
scores in identifying psychopathology in children
with epilepsy who clearly warrant mental health
interventions. They demonstrated a discrepancy
between high rate of psychiatric diagnosis and
low rate of mental health service. This shows that
cognitive functioning has an important impact on
behaviour and the importance of finding accurate
assessments and to learn and understand the needs
of this group of patients.
Despite the small number of included children,
this study has shown a good anti-seizure effect of
VNS, an improvement in seizure severity and in QOL
and a tendency to improvement over time regarding
behaviour, mood and depressive parameters. The
improvement in seizure severity, QOL, behaviour,
mood and depressive parameters was not related to
the anti-seizure effect.
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